title: [Ultrasonic monitoring as a method of preventing risks of ovarian hyperstimulation during drug therapy].
abstract: OBJECTIVE
  Ultrasonographic monitoring represents the most immediate method for an early confirmation of the onset of the worst complication of the pharmacological induction of ovulation: ovarian hyperstimulation. The aim of this study was to evaluate the incidence of this complication in a sample group of anovulatory patients receiving pharmacological treatment and undergoing repeated ultrasonographic monitoring.
  
  
  METHODS
  The authors analysed the controls performed during 1996-1997 in which a total of 413 cycles were stimulated. The patients included in the study group (mean age 28.5 years) were treated using clomiphene, oestradiol, FSH, LH and GnRH, and in 5 cases stimulation was preceded by suppression of the menstrual cycle using tryptorelin. Each patient was monitored with 3 scans, except for those treated with tryptorelin or GnRH who were more closely monitored.
  
  
  RESULTS
  In 413 patients included in this study the authors noted the onset of slight hyperstimulation in 6 cases (1.45%) which then resolved spontaneously without the need for hospitalisation.
  
  
  CONCLUSIONS
  The authors affirm that ultrasonographic monitoring represents a valid means of controlling and preventing the risks of ovarian hyperstimulation.
authors.affiliation: Dipartimento di Scienze Ginecologiche Ostetriche, Università degli Studi, Torino.
authors.forename: R
authors.initials: R
authors.lastname: Grio
authors.forename: A
authors.initials: A
authors.lastname: Patriarca
authors.forename: L
authors.initials: L
authors.lastname: Ramondini
authors.forename: L
authors.initials: L
authors.lastname: Ferrara
authors.forename: A
authors.initials: A
authors.lastname: Curti
authors.forename: R
authors.initials: R
authors.lastname: Piacentino
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D008186:Luteolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008991:Monitoring, Physiologic; D016471:Ovarian Hyperstimulation Syndrome / Q000000981:diagnostic imaging* / Q000188:drug therapy; D010053:Ovary / Q000000981:diagnostic imaging; D010062:Ovulation Induction / Q000009:adverse effects* / Q000379:methods; D011247:Pregnancy; D012307:Risk Factors; D017329:Triptorelin Pamoate / Q000008:administration & dosage* / Q000009:adverse effects; D016216:Ultrasonography, Prenatal
chemical_list: D008186:Luteolytic Agents; D017329:Triptorelin Pamoate